Although JAK2V617F is a defining mutation among MPN patients[2], the majority of JAK2V617F-negative MPN patients have JAK-STAT activation caused by a mutation in calreticulin (CALR)[3–6] or the thrombopoietin receptor (MPL)[2]. The gene discussed is CALR; the disease is myeloproliferative neoplasm.